Humana Inc. is a healthcare company based in Louisville, Kentucky, with a market cap of $29.3 billion. They offer medical and specialty insurance products, including Medicare Advantage, and operate clinical-care services through CenterWell.

Over the past year, shares of Humana have underperformed the market, declining 13.1%, while the S&P 500 gained 14.1%. On a year-to-date basis, the stock is down 4.1%.

Despite delivering better-than-expected Q3 earnings with adjusted revenue of $32.6 billion and EPS of $3.24, Humana’s stock plunged 6%. Concerns about declining profitability and narrowing margins triggered the sell-off.

Analysts expect Humana’s EPS to grow 5.4% year over year to $17.08 for the current fiscal year. The consensus rating among 27 analysts is a “Moderate Buy,” with various ratings ranging from “Strong Buy” to “Strong Sell.”

Recently, Truist Financial Corporation maintained a “Hold” rating on Humana but lowered its price target to $285, indicating a 16.3% potential upside from current levels.

Read more at Yahoo Finance: Is Wall Street Bullish or Bearish on Humana Stock?